These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11353816)

  • 1. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug.
    Mata JF; García-Manteiga JM; Lostao MP; Fernández-Veledo S; Guillén-Gómez E; Larrayoz IM; Lloberas J; Casado FJ; Pastor-Anglada M
    Mol Pharmacol; 2001 Jun; 59(6):1542-8. PubMed ID: 11353816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters.
    Mackey JR; Yao SY; Smith KM; Karpinski E; Baldwin SA; Cass CE; Young JD
    J Natl Cancer Inst; 1999 Nov; 91(21):1876-81. PubMed ID: 10547395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro evaluation of transportability and toxicity of capecitabine and its metabolites in cells derived from normal human kidney and renal cancers.
    Damaraju VL; Mowles D; Wilson M; Kuzma M; Cass CE; Sawyer MB
    Biochem Cell Biol; 2013 Dec; 91(6):419-27. PubMed ID: 24219283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes.
    Lostao MP; Mata JF; Larrayoz IM; Inzillo SM; Casado FJ; Pastor-Anglada M
    FEBS Lett; 2000 Sep; 481(2):137-40. PubMed ID: 10996312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
    Ebi H; Sigeoka Y; Saeki T; Kawada K; Igarashi T; Usubuchi N; Ueda R; Sasaki Y; Minami H
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):205-11. PubMed ID: 15844007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells.
    Cano-Soldado P; Molina-Arcas M; Algueró B; Larráyoz I; Lostao MP; Grandas A; Casado FJ; Pastor-Anglada M
    Biochem Pharmacol; 2008 Feb; 75(3):639-48. PubMed ID: 18053967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.
    García-Manteiga J; Molina-Arcas M; Casado FJ; Mazo A; Pastor-Anglada M
    Clin Cancer Res; 2003 Oct; 9(13):5000-8. PubMed ID: 14581375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
    Tabata T; Katoh M; Tokudome S; Hosakawa M; Chiba K; Nakajima M; Yokoi T
    Drug Metab Dispos; 2004 Jul; 32(7):762-7. PubMed ID: 15205393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
    Minami H; Ebi H
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2053-7. PubMed ID: 16352928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiological characterization of a recombinant human Na+-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes.
    Smith KM; Ng AM; Yao SY; Labedz KA; Knaus EE; Wiebe LI; Cass CE; Baldwin SA; Chen XZ; Karpinski E; Young JD
    J Physiol; 2004 Aug; 558(Pt 3):807-23. PubMed ID: 15194733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5'-DFUR in breast cancer MCF7 cells.
    Molina-Arcas M; Moreno-Bueno G; Cano-Soldado P; Hernández-Vargas H; Casado FJ; Palacios J; Pastor-Anglada M
    Biochem Pharmacol; 2006 Dec; 72(12):1646-56. PubMed ID: 16965766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of fused-pyrimidine nucleoside analogs with human concentrative nucleoside transporters: High-affinity inhibitors of human concentrative nucleoside transporter 1.
    Damaraju VL; Smith KM; Mowles D; Nowak I; Karpinski E; Young JD; Robins MJ; Cass CE
    Biochem Pharmacol; 2011 Jan; 81(1):82-90. PubMed ID: 20854794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
    Ait-Tihyaty M; Rachid Z; Mihalcioiu C; Jean-Claude BJ
    Breast Cancer Res Treat; 2012 May; 133(1):217-26. PubMed ID: 21915635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of uridine phosphorylase gene expression by tumor necrosis factor-alpha enhances the antiproliferative activity of the capecitabine intermediate 5'-deoxy-5-fluorouridine in breast cancer cells.
    Wan L; Cao D; Zeng J; Yan R; Pizzorno G
    Mol Pharmacol; 2006 Apr; 69(4):1389-95. PubMed ID: 16397116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1.
    Graham KA; Leithoff J; Coe IR; Mowles D; Mackey JR; Young JD; Cass CE
    Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):415-34. PubMed ID: 10772724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo.
    Nagata T; Nakamori M; Iwahashi M; Yamaue H
    Eur J Cancer; 2002 Mar; 38(5):712-7. PubMed ID: 11916555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological and clinical properties of Xeloda (Capecitabine), a new oral active derivative of fluoropyrimidine].
    Nishida M
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):549-53. PubMed ID: 14639009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
    Morita T; Matsuzaki A; Tokue A
    Int J Cancer; 2001 May; 92(3):451-6. PubMed ID: 11291085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers.
    Mackey JR; Jennings LL; Clarke ML; Santos CL; Dabbagh L; Vsianska M; Koski SL; Coupland RW; Baldwin SA; Young JD; Cass CE
    Clin Cancer Res; 2002 Jan; 8(1):110-6. PubMed ID: 11801546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential inhibition of bone metastases by 5'-deoxy-5-fluorouridine and capecitabine in the 4T1/luc mouse breast cancer model.
    Hiraga T; Hata K; Ikeda F; Kitagaki J; Fujimoto-Ouchi K; Tanaka Y; Yoneda T
    Oncol Rep; 2005 Sep; 14(3):695-9. PubMed ID: 16077977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.